Thoma Bravo Invests in Bluesight to Support Bluesight's Acquisition of Medacist
July 17, 2023
Thoma Bravo made a strategic growth investment in Bluesight to support Bluesight's acquisition of Medacist, combining two medication-management and drug-diversion analytics businesses into a single hospital pharmacy software platform. The combined company will expand Bluesight's medication intelligence capabilities and serve more than 2,000 hospitals across North America; committed financing was led by Monroe Capital and existing investor New Leaf Ventures remains invested. Financial terms were not disclosed.
- Buyers
- Thoma Bravo, Bluesight, Monroe Capital LLC
- Targets
- Medacist
- Platforms
- Bluesight
- Industry
- Healthcare Services
- Location
- Connecticut, United States
- Transaction Type
- Addon
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.